China Trade Surplus Hits $125.6 Billion as June Exports, Imports Smash Forecasts 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Dollar Eases as Middle East Conflict, Fed Outlook and Japan Pension Policy Drive FX Markets 
Asia Stocks Slip as Iran-Hormuz Tensions Lift Oil Prices, Dollar and Bond Yields 
Australian Business Conditions Hold Steady as Easing Cost Pressures Face New Oil Price Risks 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
South Korea’s KOSPI Enters Bear Market Despite Remaining 2026’s Best-Performing Major Stock Index 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Gold Price Holds Near $4,000 as Middle East Tensions and Fed Rate Hike Bets Grow 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Asian Stocks Slide as Oil Surge, U.S.-Iran Tensions and Fed Rate Bets Weigh on Markets 
Merck & Co. is said to be in advanced talks for the acquisition of Seagen, a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Fox Business reported that the acquisition deal could be valued at almost $40 billion. The amount could be more as the share price for Seagen is above $200 per share. The deal will help Merck & Co. with its expansion efforts as it adds a new acquisition to its cancer drug portfolio.
Currently, Merck’s highest-selling product is its Keytruda immunotherapy drug. The Rahway, New Jersey pharmaceutical company said that this drug accounted for $17.2 billion worth of its sales last year. As for Seagen, some of its best-selling products include Adcetris, which gathered total sales of $1.4 billion last year.
In any case, while Merck and Seagen are already in the advanced stage of negotiations, it was noted that there is still no assurance that they will be reaching an agreement for the sale of the latter.
Moreover, it was mentioned that any proposed deal in this negotiation is also expected to draw a close look from antitrust regulators. Both Merck and Seagen are still hoping to finally sign an agreement on or before Merck announces its second fiscal-quarter earnings, which has been scheduled for July 28.
Reuters reached out to Merck for comments regarding the acquisition reports, but it was not able to respond to the request immediately. On the other hand, Seagen was said to have declined to comment.
As of Wednesday, July 6, the companies are still discussing a price above $200 per share, and on that day, its closing share price was actually $175. It was added that Seagen has a market capitalization of $32.24 billion based on the records from Refinitiv data.
Meanwhile, industry observers believe that it will make sense if Merck & Co. is able to close its deal with Seagen for $250 or below. This is because this acquisition will definitely boost the company’s business and strengthen its portfolio through the latter’s exclusive cancer immunotherapy drug, Keytruda.
